Clinical and genetic analysis of five patients with familial male-limited precocious puberty
10.3760/cma.j.cn311282-20211229-00823
- VernacularTitle:家族性男性性早熟五例临床及遗传学分析
- Author:
Mali LI
1
;
Gaigai BAI
;
Shuwen HU
;
Zhihua WANG
Author Information
1. 西安市儿童医院内分泌遗传代谢科 710003
- Keywords:
Familial male-limited precocious puberty;
Peripheral precocious puberty;
LHCGR gene;
Heterozygous mutation
- From:
Chinese Journal of Endocrinology and Metabolism
2022;38(10):887-892
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical and genetic characteristics of five patients with familial male-limited precocious puberty(FMPP).Methods:The clinical data, laboratory and imaging results of the five patients with FMPP were collected. Whole exome sequencing was carried out to identify the potential variants. Suspected variants were verified by Sanger sequencing of family numbers.Results:Of the five patients, four were children and one was an adult. All the four children presented to hospital with premature sexual development at age less than 4 years. Serum testosterone was elevated, luteinizing hormone(LH) and follicle stimulating hormone(FSH) basal values were at prepubertal levels, and gonadotropin-releasing hormone(GnRH) stimulation test suggested peripheral precocious puberty. Genetic analysis revealed the mutations of LHCGR genes in all the five patients. Patients 1, 2, 3, and 4 carried the same heterozygous mutation c. 1713G>C(p.M571I), and the patient 5 carried the c. 1741T>C(p.C581R)variation. The four children were treated with anti-androgen preparations and the third-generation aromatase inhibitors, all of which were effective.Conclusion:The c. 1713G>C mutation of LHCGR gene is a novel one which expands the mutation spectrum of LHCGR gene. Combined treatment with bicaluamide and the third generation aromatase inhibitors can improve clinical symptoms and delay epiphyseal closure in children with FMPP.
